Previous 10 | Next 10 |
I will share the pros and cons of the coming battle these two companies will face in gaining market share with their competing drug. I will identify who I think will be winning this battle. Key caveat for who I think will win will be shared. For further details see: ...
WESTLAKE VILLAGE, Calif., June 03, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, will showcase its mealtime insulin soluti...
The major U.S. equity averages scored another day of notable gains, continuing a rebound that started midway through the week. The Nasdaq led the charge with a 3% advance, as the S&P 500 broke its seven-week-long weekly losing streak. Tech stocks were among the drivers of Friday's rally, ...
Bank of America launched its coverage on Liquidia Corporation (NASDAQ:LQDA) with a Buy rating after the developer of lung disease drug Yutrepia recently suffered a major setback when a rival therapy from United Therapeutics (UTHR) and MannKind (MNKD) won the FDA approval. The company shares p...
Credit Suisse increased the price target on the commercial-stage biotech United Therapeutics (NASDAQ:UTHR) after the company and its partner MannKind (MNKD) won the U.S. approval for inhalational therapy Tyvaso DPI for two lung indications. With an Outperform rating on United (UTHR), the...
The U.S. Food and Drug Administration (FDA) approved United Therapeutics (NASDAQ:UTHR) Tyvaso DPI (treprostinil) inhalation powder to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) to improve exercise ability. PAH...
Tyvaso DPI represents the second FDA-approved product utilizing MannKind’s Technosphere ® inhalation technology First approval of a dry powder inhaled treatment for PAH and PH-ILD Manufacturing of Tyvaso DPI for United Therapeutics underway at Man...
Commercial-stage biotech, United Therapeutics (NASDAQ:UTHR) and its partner MannKind (MNKD) are trading sharply higher on Monday after the FDA announced the approval of their lung disease therapy Tyvaso DPI. Accordingly, the drug-device combination is authorized to treat the pulmonary arteria...
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., May 19, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its C...
Gainers: Protagonist Therapeutics (PTGX) +10%. Marriott International (MAR) +7%. Aurora Innovation (AUR) +6%. MannKind Corporation (MNKD) +5%. Arcimoto (FUV) +5%. Losers: Enanta Pharmaceuticals (ENTA) -15%. Cisco Systems (CSCO) -12%. Limelight Networks (LLNW) -5%. Copart (CPRT) -4%....
News, Short Squeeze, Breakout and More Instantly...
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announc...
Credit and security agreement with MidCap Financial Trust repaid in full for approximately $31.6 million Convertible note issued to Mann Group LL...
Credit and security agreement with MidCap Financial Trust repaid in full for approximately $31.6 million Convertible note issued to Mann Group LLC repaid in exchange for 1.5 million shares of common stock and approximately $8.9 million Total debt reduced since December 31, 2023 ...